# Phase 1 Autoimmune Diseases trials recruiting: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials in phase 1 for Autoimmune Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Autoimmune Diseases trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/autoimmune-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07906145 | A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc) | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906145) |
| October 29, 2026 | NCT07902687 | A Clinical Study to Evaluate the Safety and Effectiveness of MSCohi-O Lens in the Treatment of Immune-related Ocular Surface Diseases. | Guangdong ProCapZoom Biosciences Co., Ltd. | Phase 1 | Not yet recruiting | Keratitis, Autoimmunity, Dry Eye Disease (DED) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902687) |
| October 21, 2026 | NCT07885605 | Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease | Ethyreal Bio, Inc. | Phase 1 | Recruiting | Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases, Exophthalmos, Orbital Diseases... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885605) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 8, 2026 | NCT07865442 | First in Human Study of ALT-01 in Healthy Participants | Altis Medicines, Inc | Phase 1 | Not yet recruiting | Autoimmune Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865442) |
| October 2, 2026 | NCT07854483 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory... | AbelZeta Inc. | Phase 1 | Not yet recruiting | Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854483) |
| July 28, 2026 | NCT07732309 | A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Antengene Biologics Limited | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732309) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| April 13, 2026 | NCT07523282 | Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523282) |
| March 6, 2026 | NCT07455578 | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | Seismic Therapeutic AU Pty Ltd | Phase 1 | Recruiting | Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO), Cutaneous Lupus... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455578) |
| February 25, 2026 | NCT07432334 | CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | Vinmec Research Institute of Stem Cell and Gene Technology | Phase 1 | Recruiting | Refractory Systemic Lupus Erythematosus | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432334) |
| January 26, 2026 | NCT07366866 | A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Autoimmune Disease | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366866) |
| December 26, 2025 | NCT07305116 | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305116) |
| December 16, 2025 | NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases | Xencor, Inc. | Phase 1 | Recruiting | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284797) |
| September 15, 2025 | NCT07171983 | A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis | Bristol-Myers Squibb | Phase 1 | Recruiting | Rheumatoid Arthritis | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07171983) |
| August 14, 2025 | NCT07123519 | A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren&#39;s Syndrome (SS), Inflammatory Myopathy... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123519) |
| August 11, 2025 | NCT07115745 | A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Recruiting | Refractory Autoimmune Diseases | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115745) |
| August 6, 2025 | NCT07105735 | RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies | The First Affiliated Hospital with Nanjing Medical University | Phase 1 | Recruiting | Autoimmune Diseases Refractory to Standard Therapies | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105735) |
| August 5, 2025 | NCT07104721 | A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104721) |
| July 25, 2025 | NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Allogene Therapeutics | Phase 1 | Recruiting | Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085104) |
| May 20, 2025 | NCT06980649 | Study of BHV-1300 in Graves' Disease | Biohaven Therapeutics Ltd. | Phase 1 | Recruiting | Graves Disease | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980649) |
| December 16, 2024 | NCT06736587 | Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Autoimmune Diseases | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736587) |
| November 27, 2024 | NCT06708845 | US Zamto-cel Autoimmune Diseases | Miltenyi Biomedicine GmbH | Phase 1 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708845) |
| October 4, 2024 | NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | Kite, A Gilead Company | Phase 1 | Recruiting | Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06626919) |
| August 22, 2024 | NCT06567080 | JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases | RenJi Hospital | Phase 1 | Not yet recruiting | B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06567080) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| Antengene Biologics Limited | 1 |
| St. Petersburg State Pavlov Medical University | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| Altis Medicines, Inc | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | 1 |
| Sonoma Biotherapeutics, Inc. | 1 |
| AbelZeta Inc. | 1 |
| Shenzhen MagicRNA Biotechnology Co., Ltd | 1 |
| National Cancer Institute (NCI) | 1 |
| [Kite, A Gilead Company](https://specstream.ai/data/clinical-trials/company/kite-a-gilead-company) | 1 |
| Stanford University | 1 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 1 |
| Guangdong Ruishun Biotech Co., Ltd | 1 |
| [Biohaven Therapeutics Ltd.](https://specstream.ai/data/clinical-trials/company/biohaven-therapeutics-ltd) | 1 |
| Seismic Therapeutic AU Pty Ltd | 1 |
| RenJi Hospital | 1 |
| Changhai Hospital | 1 |
| The Children's Hospital of Zhejiang University School of Medicine | 1 |
| R3 Stem Cell | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Guangdong ProCapZoom Biosciences Co., Ltd. | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| China | 10 |
| Australia | 6 |
| France | 3 |
| Canada | 2 |
| Germany | 2 |
| Poland | 2 |
| Russia | 1 |
| Belgium | 1 |
| Netherlands | 1 |
| Brazil | 1 |
| Czechia | 1 |
| Israel | 1 |
| Romania | 1 |
| Spain | 1 |
| India | 1 |
| South Korea | 1 |
| Vietnam | 1 |
| Sweden | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sports bars in the United States](https://specstream.ai/data/businesses/sports-bars/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
